Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The crystal structure of entinostat Form B, CHNO, has been solved and refined using laboratory X-ray powder diffraction data, and optimized using density functional techniques. Entinostat crystallizes in space group 2 and the crystal structure consists of inter-locking layers of entinostat mol-ecules parallel to the plane. A strong N-H⋯N hydrogen bond links the mol-ecules into zigzag chains propagating along the -axis direction. The graph set for this pattern is (8). Two N-H⋯O hydrogen bonds link the mol-ecules along the -axis direction. The graph sets for this pattern are (4) and (7).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412689 | PMC |
| http://dx.doi.org/10.1107/S2056989025007406 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structure of entinostat Form B, CHNO, derived using laboratory powder diffraction data and density functional techniques.
Acta Crystallogr E Crystallogr Commun
September 2025
Department of Chemistry Faculty of Science University of Lucknow,Lucknow 226007 Uttar Pradesh India.
The crystal structure of entinostat Form B, CHNO, has been solved and refined using laboratory X-ray powder diffraction data, and optimized using density functional techniques. Entinostat crystallizes in space group 2 and the crystal structure consists of inter-locking layers of entinostat mol-ecules parallel to the plane. A strong N-H⋯N hydrogen bond links the mol-ecules into zigzag chains propagating along the -axis direction.
View Article and Find Full Text PDFIn vitro and in vivo evaluation of 1,4-bis-benzylpiperazine-2-carboxylic acid derivatives as potential multi-target directed ligands (MTDLs) anti-Alzheimer's agents.
Bioorg Chem
August 2025
Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. Electronic address:
Recently, we reported a series of donepezil-based piperazine-2-carboxylic acid derivatives, essentially designed as MTDLs anti- Alzheimer's agents, with nanomolar to sub micromolar dual inhibitory activity against acetylcholinesterase and butyrylcholinesterase. Herein, we report the evaluation of selected series of the designed compounds 4(c, d), 5(b, c), 7(a-f), 8(a, b, f), for potential activity against further clinical traits involved in the pathogenesis of Alzheimer's disease (AD). The results revealed compounds 7b and 8f with promising in vitro inhibitory effect against Aβ aggregation (IC = 1.
View Article and Find Full Text PDFDevelopment of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents.
J Enzyme Inhib Med Chem
December 2025
School of Chemistry, University of Leeds, Leeds, UK.
Small molecule inhibitors of lysine deacetylases (KDACs), exemplified by histone deacetylases (HDACs), exhibit significant promise as cancer therapeutics. Using a modular combinatorial chemistry approach, a novel class of KDAC inhibitors (KDACi) containing the aminophenyl-benzamide headgroup have been developed, which incorporate a vinyl group within the linker region for active site stabilisation and a trifluoromethyl moiety within the capping group to exploit enzyme surface topology. Consequently, a class I selective KDACi () with a preference towards HDAC1 over other class I KDACs was identified.
View Article and Find Full Text PDFOral Biomimetic Nanotherapeutics for Ulcerative Colitis Targeted Treatment by Repairing Intestinal Epithelial Barrier and Restoring Redox Homeostasis.
ACS Appl Mater Interfaces
January 2025
Department of Pharmaceutics, School of Pharmacy, Ningxia Medical University, No. 1160 Shengli South Street, Yinchuan 750004, PR China.
The structural disruption of intestinal barrier and excessive reactive oxygen/nitrogen species (RONS) generation are two intertwined factors that drive the occurrence and development of ulcerative colitis (UC). Synchronously restoring the intestinal barrier and mitigating excess RONS is a promising strategy for UC management, but its treatment outcomes are still hindered by low drug accumulation and retention in colonic lesions. Inspired by intestine colonizing bacterium, we developed a mucoadhesive probiotic -mimic entinostat-loaded hollow mesopores prussian blue (HMPB) nanotherapeutic (AM@HMPB@E) for UC-targeted therapy via repairing intestinal barrier and scavenging RONS.
View Article and Find Full Text PDFTriple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer.
Cancers (Basel)
October 2024
Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany.
Background/objectives: Cisplatin is part of the first-line treatment of advanced urothelial carcinoma. Cisplatin resistance is a major problem but may be overcome by combination treatments such as targeting epigenetic aberrances. Here, we investigated the effect of the class I HDACi entinostat and bromodomain inhibitors (BETis) on the potency of cisplatin in two pairs of sensitive and cisplatin-resistant bladder cancer cell lines.
View Article and Find Full Text PDF